LUNG CANCER - ERLOTINIB

NICE Appraisal

TA162  Erlotinib for the treatment of non-small cell lung cancer (November 2008)

 

DSU Reports

Erlotinib for the treatment of non-small cell lung cancer: Report from the Decision Support Unit in response to additional data submitted by Roche  (January 2008)

The risk and costs of febrile neutropenia in patients with non-small cell lung cancer treated with docetaxel  (December 2007)

 

Related publications

A Wailoo, A Sutton, A Morgan, The risk of febrile neutropenia in patients with non-small cell lung cancer treated with Docetaxel: a systematic review and meta-analysis 2009  British Journal of Cancer Vol 100: 436-441

 

To receive notification when new reports or documents are uploaded to this website, please join our mailing list by entering your details on the right of this page or follow us on Twitter @NICE_DSU